A fault while following the described protocols for the assembly of defined supramolecular structures mainly leads either to the formation of unspecific aggregates (Figure 2, IV) or to homogeneously distributed ELP-amphiphiles. Critical steps of the protocol are discussed below:
For high expression yield of the amphiphilic ELP, a relatively low temperature of 20°C is optimal. For successful affinity based purification of the amphiphilic ELP an urea concentration of 4 M in the lysis buffer was proven to best solubilize the amphiphilic ELP and increase the protein yield in the soluble elution fraction. If lower urea concentrations in the lysis buffer are desired, affinity purification must be tested for the individual constructs. 2 M urea worked as well for some constructs, especially for those where the His-tag was fused to the hydrophilic domain and therefore still able to bind the resin. An additional purification step after His-tag purification via size exclusion chromatography can increase the vesicle yield as well.
In case of applying the THF-swelling protocol, the amphiphilic ELP needs to be labeled with a fluorescent organic dye for visualization. Importantly for the BDP labeling of the amphiphilic ELP (see supplementary information for amino acid sequences containing UAA pAzF) via SPAAC is the absence of any reductant such as TCEP, DTT nor β-mercaptoethanol in all purification buffers. This is necessary to avoid the well reported azide to amine reduction of pAzF prior to the SPAAC reaction24.
The exact reaction stoichiometry of dye to amphiphilic ELP (e.g. pAzF-R40F20) is not crucial since it is not necessary to label every single ELP molecule for simple vesicle visualization via epifluorescence microscopy. Therefore, the correlation of a reference SDS gel band and the corresponding weighted lyophilized sample is only necessary once for each protein construct. However, if close to 100% labeling yield is desired a ratio of 1:1 equivalents dye to ELP molecules is sufficient. Very similar amphiphilic ELPs were analyzed in our lab to be fully labeled at an equimolar addition of BDP (data not yet published).
For vesicle preparation using the THF swelling method, the most critical steps are the swelling of lyophilized amphiphilic ELP and subsequent stratification of this solution on top of the aqueous buffer phase. Therefore, the freshly lyophilized amphiphilic ELP should be as anhydrous as possible, which can be achieved by ventilation of the lyophilizer with dry nitrogen gas and immediate closure of the reaction tube lids. If available, septum sealed dry THF should be used to increase the vesicle yield, but THF p.a. (>99.5%) without septum works as well. The stratification step upon swelling the amphiphilic ELP in dry THF should be executed very carefully. Successful stratification of the two temperature-controlled solutions leads to a clearly visible phase boundary between organic and aqueous phase. The initial stratification step should be conducted slowly even though elevated temperatures lead to thermal induced mixing of these phases. Emergent turbidity of the solution is due to light scattering of formed vesicles, fibers or coacervates. In control samples lacking the protein, no turbidity appears though small sized structures (up to 200 nm) are reported for the THF water-interface25. The THF stratification step is the most critical and failure prone step of the swelling protocol. After the incubation step the supramolecular structures can be dialyzed against buffer or ultrapure water. Preferentially the same aqueous solution should be used which was applied for initial assembly in order to maintain the osmolarity and prevent swelling or shrinking of the assembled vesicles. After dialysis, the vesicles, fibers and coacervates are usually stable for at least one week. Depending on the environmental parameters during assembly often a small proportion of other supramolecular structures besides the main structure are present if the THF swelling method is applied8. The described THF method increases the vesicle assembly yield by one order of magnitude while the BuOH extrusion improves the yield by three orders of magnitude compared to our previously published in vitro method5.
The BuOH extrusion method is applied to obtain exclusively stable vesicular structures with high reproducibility, circumventing fibers and spherical coacervates. This method is less error prone and compatible with fluorescent proteins. Therefore F20R20-mEGFP or F20R20-mCherry can be applied as well as BDP-R40F20 or BDP-E20F20. The only critical step is the rapid mixing of the aqueous protein solution after addition of 10%–20% v/v BuOH. The F20R20-mEGFP or F20R20-mCherry concentration should be around 1–15 µM. By applying BuOH extrusion method vesicles can be assembled in ultrapure water or buffer containing up to 5 M NaCl or 4 M urea and pH ranging from 5 to 8. Extruded PMBCs in 20% v/v BuOH can be stored for at least 6 months at 4°C while preserving their vesicular structure. To narrow the vesicle size distribution, they can be extruded using a mini extruder through a membrane of 0.2-1 µm pore size. This pore extrusion can be done directly after BuOH addition to the amphiphilic ELP or after vesicle assembly. If PMBCs are too concentrated for imaging, assembled vesicles in BuOH can be diluted through rapid mixing using aqueous buffer containing 10%–20% v/v BuOH.
The major limitation of the BuOH extrusion method is that PMBC dialysis against aqueous buffers often results in poor vesicle yield. Further, the presence of residual BuOH within the membrane space cannot be excluded since simple fatty acids were able to incorporate into the PMBC membrane21. Therefore, PMBC membranes might be to some extent be composed of protein and alkanol moieties.
Encapsulation of chemically diverse cargo molecules works best using the BuOH extrusion method. Further, DMSO as solvent for the stock solution of the dye to be captured increases the dye encapsulation efficiency. For delicate cargo to be encapsulated, 5%–10% v/v 1-octanol can be used for PMBC assembly and has been proven to be better compatible, when compared to BuOH, with functional encapsulated enzymes such as DNA-ligase or TEV protease21,26. However, due to the shorter chain length of n-butanol it can be dialyzed against aqueous buffer in contrast to 1-octanol, which is not able to permeate the applied dialysis-membrane. Another method limitation is that the applied temperatures and pH values needed to control the desired suprastructure formation can affect enzyme activity. In future work, affinity purification or size exclusion purification should be established to separate non-encapsulated versus encapsulated molecules without deteriorating vesicle membrane integrity.
In contrast to film rehydration methods16,17 the herein described protocols enable the assembly of vesicles sizes greater than 600 nm. This allows monitoring of real time fusion events through simple epifluorescence microscopy and the observation of membrane phase separation8. Compared to temperature triggered vesicular assembly of amphiphilic ELP9 the protocols described here yield PMBC with a long time stability of up to 6 month. However, the main disadvantage is the need of organic solvent for structure formation. Even though BuOH fully preserves the integrity and function of fluorescent proteins27 (data not shown), the activity of encapsulated enzymes might be restricted by residual organic solvent and must be tested individually. However, catalytic reactions involving DNA- ligase, TEV-protease and lipase have been successfully conducted within the luminal space of the vesicles, assembled by 1-octanol or BuOH extrusion26,21. Additionally, even though THF dialysis after assembly is very unproblematic and vesicle integrity is preserved, the BuOH removal frequently results in loss of vesicle integrity due to unknown reasons.
The described protocols enable researchers to assemble micrometer and sub micrometer sized supramolecular structures with distinct physicochemical properties, good encapsulation properties, and long time stability. These supramolecular structures can be applied for the design of minimal cells26 or artificial cell research21, enzyme encapsulation, or drug formulation. The presented functional PMBCs are further promising candidates for drug delivery, since their building blocks are not immunogenic28, exhibit dynamic fusion behavior, and allow for diverse cargo encapsulation.